Why Tricuspid Regurgitation Was Called the "Forgotten" Valve Disease
For decades, the tricuspid valve received far less attention than its counterparts on the left side of the heart. The aortic valve and mitral valve captured the spotlight in cardiology conferences, surgical training programs, and clinical research. Tricuspid regurgitation — the backward leaking of blood through the tricuspid valve — was often dismissed as something that would "take care of itself" once left-sided heart disease was addressed.
That thinking has changed dramatically. We now understand that significant tricuspid regurgitation, left untreated, is associated with reduced survival, recurrent heart failure hospitalizations, and a progressively worsening quality of life. Studies published in the Journal of the American College of Cardiology have shown that even moderate-to-severe TR is an independent predictor of mortality, regardless of whether left ventricular function is preserved.
If you or a family member has been told you have tricuspid regurgitation that may need treatment, understanding your options is critical. The decisions made now — including whether to treat, when to treat, and how to treat — can significantly affect long-term outcomes.
Understanding Tricuspid Regurgitation: What Is Actually Happening
The tricuspid valve sits between the right atrium and right ventricle. Its job is straightforward: allow blood to flow forward into the right ventricle during filling, then close tightly when the ventricle contracts to push blood toward the lungs. When the valve leaks, blood flows backward into the right atrium and, eventually, into the veins of the body.
This backward flow causes the symptoms many patients experience:
- Leg and ankle swelling (peripheral edema)
- Abdominal bloating and fluid accumulation (ascites)
- Fatigue and exercise intolerance
- A pulsing sensation in the neck (from distended jugular veins)
- Liver congestion, which can progress to cardiac cirrhosis in severe cases
Primary vs. Secondary Tricuspid Regurgitation
This distinction matters enormously for treatment planning:
Primary TR results from a structural problem with the valve itself — damaged leaflets from endocarditis, rheumatic disease, trauma, or a congenital abnormality such as Ebstein's anomaly. Primary TR accounts for roughly 10-15% of cases requiring intervention.
Secondary (functional) TR is far more common. Here, the valve leaflets are structurally normal, but the tricuspid annulus (the ring of tissue the leaflets attach to) has dilated because of right ventricular enlargement, pulmonary hypertension, left-sided heart disease, or atrial fibrillation. The leaflets simply cannot coapt — they cannot meet in the middle to form a seal.
Understanding which type of TR you have is essential, because it directly influences whether tricuspid regurgitation treatment should focus on the valve alone, the underlying condition driving the problem, or both.
When Does Tricuspid Valve Surgery Become Necessary?
Not every patient with tricuspid regurgitation needs surgery. Mild TR is common and often clinically insignificant. But the decision-making becomes nuanced as severity progresses.
According to the 2020 ACC/AHA guidelines for management of valvular heart disease, tricuspid valve surgery is recommended in the following scenarios:
- Severe TR in patients already undergoing left-sided valve surgery — This is a Class I recommendation. If a surgeon is already operating on the mitral or aortic valve and significant TR is present, addressing the tricuspid valve at the same time is strongly supported by evidence. Failing to do so often leads to progressive TR and the need for a high-risk reoperation later.
- Severe primary TR causing symptoms — When the valve itself is diseased and medical therapy has not controlled symptoms, surgical intervention is warranted.
- Progressive tricuspid annular dilation (≥40 mm or >21 mm/m²) even with less-than-severe TR in patients undergoing left-sided surgery — This reflects the understanding that a dilated annulus will likely worsen over time.
- Isolated severe TR with symptoms or progressive right ventricular dilation — This is a more recent and evolving indication, and one where the timing of intervention is critical.
The challenge with tricuspid valve disease is that it can progress silently. By the time symptoms become obvious, the right ventricle may already be significantly dilated and weakened. Surgical risk increases substantially when the right ventricle has begun to fail. This is why earlier referral and evaluation are so important.
If you have been diagnosed with severe TR and are uncertain about timing, using a free cardiac surgery risk calculator can give you a baseline understanding of your operative risk profile, though it is no substitute for a thorough surgical evaluation.
TR Repair Options: Surgical and Catheter-Based Approaches
The treatment landscape for tricuspid regurgitation has expanded significantly in recent years. Here is what you should know about each approach.
Tricuspid Valve Repair (Surgical)
When feasible, repair is generally preferred over replacement. Surgical tricuspid valve repair most commonly involves:
- Annuloplasty — Placing a rigid or semi-rigid ring around the dilated tricuspid annulus to restore its normal size and shape. This is the most frequently performed tricuspid repair technique and is highly effective for secondary TR when the leaflets themselves are normal. Ring annuloplasty has demonstrated superior long-term durability compared to suture-based (DeVega) techniques.
- Leaflet repair — In cases of primary TR, surgeons may repair torn or prolapsing leaflets using techniques similar to those used in mitral valve repair.
- Chordal procedures — Artificial chords (neochords) can be placed to support leaflets that have lost their normal support structure.
Surgical repair carries excellent outcomes when performed at the right time and by experienced surgeons. Operative mortality for tricuspid repair done in conjunction with left-sided valve surgery is generally in the range of 3-8%, though this varies significantly based on patient comorbidities and right ventricular function.
Tricuspid Valve Replacement (Surgical)
When repair is not technically feasible — typically in cases of severe leaflet destruction, significant tethering, or failed prior repair — tricuspid valve replacement is performed. This involves removing the diseased valve and implanting either a bioprosthetic (tissue) valve or a mechanical valve.
Key considerations:
- Bioprosthetic valves are used more frequently in the tricuspid position because the lower pressures on the right side of the heart are associated with slower degeneration. However, these valves do wear out over time, particularly in younger patients.
- Mechanical valves offer durability but require lifelong anticoagulation with warfarin, which carries bleeding risks.
- Isolated tricuspid valve replacement (reoperation for TR after prior left-sided surgery) carries higher operative mortality — reported in some series at 8-15% — partly because these patients often present late with advanced right heart failure, liver dysfunction, and other comorbidities.
This elevated risk with isolated reoperation is precisely why addressing the tricuspid valve during initial left-sided surgery, when indicated, is so important.
Catheter-Based (Transcatheter) TR Repair Options
The development of transcatheter tricuspid valve interventions represents one of the most exciting advances in this field. These less-invasive approaches aim to reduce TR without open-heart surgery, which is particularly relevant for patients considered too high-risk for conventional surgery.
Several devices and strategies are in various stages of clinical use and investigation:
- Edge-to-edge repair (e.g., TriClip) — Similar in concept to the MitraClip used for mitral regurgitation, this device clips the tricuspid valve leaflets together to reduce the regurgitant orifice. The TRILUMINATE Pivotal trial demonstrated meaningful reduction in TR severity and improvement in quality of life, leading to FDA approval of the TriClip system in 2023.
- Transcatheter annuloplasty devices — These aim to replicate the effect of surgical annuloplasty through a catheter-based approach.
- Transcatheter tricuspid valve replacement (TTVR) — Several valve systems are in clinical trials, offering the potential for complete valve replacement via catheter in patients who cannot undergo open surgery.
- Caval valve implantation — In select patients, placing a valve in the inferior vena cava can reduce the hemodynamic consequences of severe TR even without directly treating the tricuspid valve itself.
It is important to understand that while these catheter-based TR repair options are promising, they are still evolving. Long-term durability data is limited compared to decades of surgical experience. Not every patient is an appropriate candidate, and the degree of TR reduction achieved with transcatheter approaches may be less complete than what surgery can deliver.
How to Make the Right Decision About Tricuspid Regurgitation Treatment
The decision about how to treat TR involves weighing multiple factors simultaneously:
- Severity and mechanism of TR — Is this primary or secondary? How severe is the leak? Is the annulus significantly dilated?
- Right ventricular function — A weakened right ventricle significantly increases surgical risk and may influence the choice between surgical and transcatheter approaches.
- Concurrent cardiac conditions — Is left-sided valve surgery also needed? Is there atrial fibrillation that should be addressed? Is coronary artery disease present?
- Overall health and operative risk — Kidney function, liver function, nutritional status, frailty, and pulmonary hypertension all impact risk assessment.
- Timing — Operating too late, after irreversible right ventricular damage, is a well-recognized problem. But operating unnecessarily on mild disease also exposes patients to risk without clear benefit.
This is an area where the nuances truly matter. Guidelines provide a framework, but the application of those guidelines to your specific anatomy, physiology, and life circumstances requires expert judgment.
The Value of a Second Opinion
Tricuspid valve disease management is evolving rapidly. The surgeon or cardiologist you see may have a strong preference for one approach based on their training and institutional capabilities, but that does not mean it is the only — or the best — option for you. Heart teams at high-volume centers may offer surgical, transcatheter, and medical management options that are not available everywhere.
A cardiac surgery second opinion provides an independent, expert review of your imaging, hemodynamics, and overall clinical picture. It can confirm that the recommended plan is appropriate, suggest modifications, or identify alternatives you were not offered.
Practical Advice for Patients With Tricuspid Regurgitation
Based on my experience as a cardiovascular surgeon, here is what I tell patients and families navigating a TR diagnosis:
- Do not accept the outdated narrative that TR is benign. Significant tricuspid regurgitation affects survival. If you have been told "we will just watch it" for years while your symptoms worsen, it is reasonable to seek another perspective.
- Get a high-quality echocardiogram. The assessment of TR severity can vary between sonographers and readers. If major decisions are being made, ensure the imaging is thorough and interpreted by experienced physicians.
- Ask about the right ventricle. The status of your right ventricle is arguably the most important factor in determining both the urgency and risk of intervention. Ask your doctors how your right ventricle is functioning.
- Understand your complete picture. TR rarely exists in isolation. Knowing whether you have pulmonary hypertension, atrial fibrillation, left-sided valve disease, or other conditions is essential for proper treatment planning.
- Ask about volume and experience. Tricuspid valve surgery outcomes are better at centers that perform these procedures regularly. This is not the time for a surgeon who does one or two tricuspid cases per year.
If you are facing a decision about tricuspid regurgitation treatment — whether you have been told you need surgery, have been offered a transcatheter procedure, or are uncertain about whether your TR should be treated at all — a WhiteGloveMD second opinion can help. Our AI-powered platform, led by a board-certified cardiovascular surgeon, provides a thorough, independent review of your records and delivers clear, actionable guidance. Start your review today and make your next decision with confidence.